William A Blumentals1, Xue Song. 1. Medical Data Analytics, Roche Laboratories, Nutley, New Jersey, USA. william.blumentals@roche.com
Abstract
CONTEXT: Recently, neuropsychiatric events associated with oseltamivir treatment have been reported, mainly in pediatric patients in Japan. OBJECTIVE: To explore the influence of oseltamivir treatment on central nervous system (CNS)-related and neuropsychiatric events in adults, children, and adolescents with influenza. DESIGN: A retrospective cohort study using propensity-matched data for 6 influenza seasons (2000-2006). SETTING: Claims data were obtained from the Thomson Healthcare MarketScan Research Database. PATIENTS: Patients of all ages and in subgroups aged 12 years or younger, 13-17 years, and 18-49 years diagnosed with influenza. MAIN OUTCOME MEASURES: Claims for CNS and neuropsychiatric events within 14 and 30 days following influenza diagnosis were compared between patients prescribed oseltamivir and those not prescribed antiviral treatment. RESULTS: Data for 40,704 patients prescribed oseltamivir (9599 aged 12 years or younger; 4615, 13-17 years; and 16,910, 18-49 years) and 40,704 matched controls (9599 aged 12 years or younger; 4621, 13-17 years; and 16,898, 18-49 years) were analyzed. None of the CNS-related and neuropsychiatric events was more likely to occur in patients prescribed oseltamivir. Overall, CNS-related or neuropsychiatric events (odds ratio [OR] 0.76; 95% confidence intervals [CI]: 0.68, 0.84), psychiatric events (OR 0.82; 95% CI: 0.70, 0.96), and disturbances of consciousness (OR 0.61; 95% CI: 0.48, 0.76) within 14 days after influenza diagnosis were all less likely in patients given oseltamivir. Findings were similar within the 30-day post-index time window and across all age groups. CONCLUSIONS: No increase in CNS-related and neuropsychiatric events was observed in adults, children, or adolescents with influenza who were prescribed oseltamivir in this study.
CONTEXT: Recently, neuropsychiatric events associated with oseltamivir treatment have been reported, mainly in pediatric patients in Japan. OBJECTIVE: To explore the influence of oseltamivir treatment on central nervous system (CNS)-related and neuropsychiatric events in adults, children, and adolescents with influenza. DESIGN: A retrospective cohort study using propensity-matched data for 6 influenza seasons (2000-2006). SETTING: Claims data were obtained from the Thomson Healthcare MarketScan Research Database. PATIENTS: Patients of all ages and in subgroups aged 12 years or younger, 13-17 years, and 18-49 years diagnosed with influenza. MAIN OUTCOME MEASURES: Claims for CNS and neuropsychiatric events within 14 and 30 days following influenza diagnosis were compared between patients prescribed oseltamivir and those not prescribed antiviral treatment. RESULTS: Data for 40,704 patients prescribed oseltamivir (9599 aged 12 years or younger; 4615, 13-17 years; and 16,910, 18-49 years) and 40,704 matched controls (9599 aged 12 years or younger; 4621, 13-17 years; and 16,898, 18-49 years) were analyzed. None of the CNS-related and neuropsychiatric events was more likely to occur in patients prescribed oseltamivir. Overall, CNS-related or neuropsychiatric events (odds ratio [OR] 0.76; 95% confidence intervals [CI]: 0.68, 0.84), psychiatric events (OR 0.82; 95% CI: 0.70, 0.96), and disturbances of consciousness (OR 0.61; 95% CI: 0.48, 0.76) within 14 days after influenza diagnosis were all less likely in patients given oseltamivir. Findings were similar within the 30-day post-index time window and across all age groups. CONCLUSIONS: No increase in CNS-related and neuropsychiatric events was observed in adults, children, or adolescents with influenza who were prescribed oseltamivir in this study.
Authors: R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward Journal: Pediatr Infect Dis J Date: 2001-02 Impact factor: 2.129
Authors: J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills Journal: JAMA Date: 2000-02-23 Impact factor: 56.272
Authors: K G Nicholson; F Y Aoki; A D Osterhaus; S Trottier; O Carewicz; C H Mercier; A Rode; N Kinnersley; P Ward Journal: Lancet Date: 2000-05-27 Impact factor: 79.321
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Jason G Newland; José R Romero; Meera Varman; Casey Drake; Amy Holst; Tom Safranek; Kanta Subbarao Journal: Clin Infect Dis Date: 2003-03-20 Impact factor: 9.079
Authors: Nancy Santesso; Jonathan Hsu; Reem Mustafa; Jan Brozek; Yao Long Chen; Jessica P Hopkins; Adrienne Cheung; Gayane Hovhannisyan; Liudmila Ivanova; Signe A Flottorp; Ingvil Saeterdal; Arthur D Wong; Jinhui Tian; Timothy M Uyeki; Elie A Akl; Pablo Alonso-Coello; Fiona Smaill; Holger J Schünemann Journal: Influenza Other Respir Viruses Date: 2013-09 Impact factor: 4.380
Authors: Jonathan Hsu; Nancy Santesso; Reem Mustafa; Jan Brozek; Yao Long Chen; Jessica P Hopkins; Adrienne Cheung; Gayane Hovhannisyan; Liudmila Ivanova; Signe A Flottorp; Ingvil Saeterdal; Arthur D Wong; Jinhui Tian; Timothy M Uyeki; Elie A Akl; Pablo Alonso-Coello; Fiona Smaill; Holger J Schünemann Journal: Ann Intern Med Date: 2012-02-27 Impact factor: 25.391
Authors: S S Jhee; M Yen; L Ereshefsky; M Leibowitz; M Schulte; B Kaeser; L Boak; A Patel; G Hoffmann; E P Prinssen; C R Rayner Journal: Antimicrob Agents Chemother Date: 2008-08-01 Impact factor: 5.191